Brokers Issue Forecasts for DNLI Q1 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued to clients and investors on Friday, November 8th. B. Riley analyst M. Mamtani expects that the company will earn ($0.77) per share for the quarter. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.62) per share. B. Riley also issued estimates for Denali Therapeutics' Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($2.26) EPS and FY2027 earnings at ($1.20) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) earnings per share.

Other analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Thursday. Cantor Fitzgerald cut shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, October 7th. Jefferies Financial Group raised their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, Wedbush decreased their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.90.

Denali Therapeutics Stock Up 3.2 %

Denali Therapeutics stock traded up $1.00 during trading hours on Monday, hitting $32.35. The stock had a trading volume of 418,074 shares, compared to its average volume of 1,067,958. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The stock's 50-day moving average price is $27.81 and its 200-day moving average price is $23.62.

Insiders Place Their Bets

In related news, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Denali Therapeutics by 879.5% during the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after buying an additional 1,847 shares during the period. CWM LLC increased its holdings in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC bought a new position in shares of Denali Therapeutics in the 3rd quarter worth $73,000. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth $88,000. Finally, Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.